A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Trial Details

NCT ID

NCT06616636

Phase

PHASE1

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• Azacitidine
• Rezatapopt

Locations (sample)

• Tampa, Florida, United States|27.94752,-82.45843
• Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

• Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
• Patient is willing and able to adhere to the study visit schedule and other protocol requirements.
• Patient has relapsed or primary refractory AML or MDS
• Any other comorbidity that per the investigator renders a patient inappropriate for intensive chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.